{"title": "Impfung gegen humane Papillomviren. Wirksamkeit und Nebenwirkungen - Die Gyn\u00e4kologie", "author": "Eggersmann; T K; Gallwas; J; Mahner; S; Dannecker; C", "url": "https://link.springer.com/article/10.1007/s00129-017-4123-2", "hostname": "springer.com", "description": "The development of a vaccine against human papillomavirus (HPV) is a milestone in the prevention of HPV-related disease. HPV infection is the most common cause of anogenital diseases. Although the majority of HPV infections do not cause symptoms and resolve spontaneously, persistent infection with specific HPV types (most frequently HPV 16 and HPV 18) may lead to precancerous lesions which may progress to cervical cancer. HPV infection is also associated with other anogenital cancers (vulva, vagina, penis, anus) and head and neck cancer. The vaccines are safe and effective. Current evidence supports the recommendation of prophylactic vaccination. Therapeutic vaccines are under development. This article discusses the efficacy and adverse effects of various HPV vaccines available on the German market.", "sitename": "SpringerLink", "date": "2017-08-23", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Zusammenfassung\nDie Entwicklung einer Impfung gegen humane Papillomviren (HPV) stellte einen Meilenstein in der Pr\u00e4vention HPV-assoziierter Erkrankungen dar. Die HPV-Infektion ist die h\u00e4ufigste Ursache anogenitaler Ver\u00e4nderungen. Die Mehrheit der HPV-Infektionen ist symptomlos und heilt spontan aus. Persistierende Infektionen mit spezifischen HPV-Typen (meistens HPV 16 und 18) k\u00f6nnen zu Krebsvorstufen f\u00fchren, die sich zu einem Zervixkarzinom entwickeln k\u00f6nnen. Bei beiden Geschlechtern ist die HPV-Infektion au\u00dferdem mit Karzinomen in den Bereichen Anogenitaltrakt (Vulva, Vagina, Penis, Anus) und Oropharynx assoziiert. Die vorhandenen Impfstoffe sind sicher und effektiv. Die bisherig erhobenen Daten unterstreichen den prophylaktischen Charakter der HPV-Impfung; Impfstoffe zur Behandlung einer bestehenden HPV-Infektion befinden sich in Entwicklung. Ziel des Beitrags ist die Darstellung der Effektivit\u00e4t und die Beleuchtung des Nebenwirkungsprofils der sich auf dem deutschen Markt befindlichen HPV-Impfstoffe im Vergleich.\nAbstract\nThe development of a vaccine against human papillomavirus (HPV) is a milestone in the prevention of HPV-related disease. HPV infection is the most common cause of anogenital diseases. Although the majority of HPV infections do not cause symptoms and resolve spontaneously, persistent infection with specific HPV types (most frequently HPV 16 and HPV 18) may lead to precancerous lesions which may progress to cervical cancer. HPV infection is also associated with other anogenital cancers (vulva, vagina, penis, anus) and head and neck cancer. The vaccines are safe and effective. Current evidence supports the recommendation of prophylactic vaccination. Therapeutic vaccines are under development. This article discusses the efficacy and adverse effects of various HPV vaccines available on the German market.\nThis is a preview of subscription content,\n[access via\nyour institution](//wayf.springernature.com?redirect_uri=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00129-017-4123-2%3Ferror%3Dcookies_not_supported%26code%3Df29823a0-0cdc-4b37-9d55-de44ef29e7ee).\nAccess options\nBuy single article\nInstant access to the full article PDF.\n39,95 \u20ac\nPrice includes VAT (Germany)\nLiteratur\nAnonymous (2017) Human Papillomavirus 9\u2011valent vaccine, recombinant, package insert. http:/fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/UCM426457.pdf\nAnonymous (2017) Human Papillomavirus bivalent (types 16,18) vaccine, recombinant, package insert. http:/fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/UCM186981.pdf\nAnonymous (2017) Human Papillomavirus Quadrivalent (Types 6,11,16,18) Vaccine, Recombinant, Package Insert. http:/fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/UCM111263.pdf\nAnonymous (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356:1915\u20131927\nWorld Health Organization (2017) Immunization Vaccines and Biologicals - HumanPapillomavirus. http://www.who.int/immunization/diseases/hpv/en/\nDe Sanjose S, Quint WG, Alemany L et al (2010) Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol 11:1048\u20131056\nGarland SM, Ault KA, Gall SA et al (2009) Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: A combined analysis of five randomized controlled trials. Obstet Gynecol 114:1179\u20131188\nGarland SM, Hernandez-Avila M, Wheeler CM et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928\u20131943\nGarland SM, Kjaer SK, Munoz N et al (2016) Impact and effectiveness of the Quadrivalent human Papillomavirus vaccine: A systematic review of 10 years of real-world experience. Clin Infect Dis 63:519\u2013527\nGee J, Naleway A, Shui I et al (2011) Monitoring the safety of quadrivalent human papillomavirus vaccine: Findings from the Vaccine Safety Datalink. Vaccine 29:8279\u20138284\nGee J, Weinbaum C, Sukumaran L et al (2016) Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States. Hum Vaccines Immunother 12:1406\u20131417\nGiuliano AR, Palefsky JM, Goldstone S et al (2011) Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 364:401\u2013411\nGoss MA, Lievano F, Buchanan KM et al (2015) Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine. Vaccine 33:3422\u20133428\nHerrero R, Quint W, Hildesheim A et al (2013) Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLOS ONE 8:e68329\nHildesheim A, Wacholder S, Catteau G et al (2014) Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 32:5087\u20135097\nHoyert DL, Xu J (2012) Deaths: Preliminary data for 2011. Natl Vital Stat Rep 61:1\u201351\nhttp://Apps.Who.Int/Iris/Bitstream/10665/255353/1/Wer9219.Pdf?Ua=1\nHuang LM, Puthanakit T, Cheng-Hsun C et al (2017) Sustained Immunogenicity of 2\u2011dose human Papillomavirus 16/18 AS04-adjuvanted vaccine schedules in girls aged 9\u201314 years: A randomized trial. J Infect Dis. https://doi.org/10.1093/infdis/jix154. PMID:28591778\nJoura EA, Giuliano AR, Iversen OE et al (2015) A 9\u2011valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372:711\u2013723\nKjaer SK, Sigurdsson K, Iversen OE et al (2009) A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2:868\u2013878\nRobert-Koch-Institut (2016) Epidemiol Bull 16:137\u2013138\nLehtinen M, Paavonen J, Wheeler CM et al (2012) Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4\u2011year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13:89\u201399\nMarkowitz LE, Dunne EF, Saraiya M et al (2014) Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep Recomm Rep 63:1\u201330\nMccarthy NL, Gee J, Sukumaran L et al (2016) Vaccination and 30-day mortality risk in children, adolescents, and young adults. Pediatrics 137:e20152970\nMcneil MM, Weintraub ES, Duffy J et al (2016) Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol 137:868\u2013878\nMeites E, Kempe A, Markowitz LE (2017) Use of a 2-dose schedule for human Papillomavirus vaccination-updated recommendations of the advisory committee on immunization practices. Am J Transplant 17:834\u2013837\nNaud PS, Roteli-Martins CM, De Carvalho NS et al (2014) Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: Final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother 10:2147\u20132162\nPaavonen J, Naud P, Salmeron J et al (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301\u2013314\nPalefsky JM, Giuliano AR, Goldstone S et al (2011) HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 365:1576\u20131585\nScheller NM, Pasternak B, Svanstrom H et al (2014) Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism. JAMA 312:187\u2013188\nScheller NM, Svanstrom H, Pasternak B et al (2015) Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA 313:54\u201361\nSkinner SR, Szarewski A, Romanowski B et al (2014) Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4\u2011year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet 384:2213\u20132227\nWheeler CM, Skinner SR, Del Rosario-Raymundo MR et al (2016) Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7\u2011year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis 16:1154\u20131168\nZhu FC, Hu SY, Hong Y et al (2017) Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18\u201325 years: Event-triggered analysis of a randomized controlled trial. Cancer Med 6:12\u201325\nEthics declarations\nInteressenkonflikt\nT. K. Eggersmann gibt an, dass kein Interessenkonflikt besteht. J. Gallwas und C. Dannecker geben an, dass sie Honorarvortr\u00e4ge f\u00fcr GlaxoSmithKline und MSD Sharp & Dohme GmbH gehalten haben. S. Mahner gibt an, dass er Forschungsf\u00f6rderung, Reisekostenerstattung, Honorare oder Beratungst\u00e4tigkeit von AstraZeneca, Bayer, Boehringer Ingelheim, Clovis, Eisai, GlaxoSmithKline, Jenapharm, Janssen-Cilag, Medac, MSD, PharmaMar, Roche, Sensor Kinesis, Teva und Tesaro erhalten hat.\nDieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.\nAdditional information\nRedaktion\nM. Kiechle, M\u00fcnchen\nRights and permissions\nAbout this article\nCite this article\nEggersmann, T.K., Gallwas, J., Mahner, S. et al. Impfung gegen humane Papillomviren. Wirksamkeit und Nebenwirkungen. Gyn\u00e4kologe 50, 682\u2013686 (2017). https://doi.org/10.1007/s00129-017-4123-2\nPublished:\nIssue Date:\nDOI: https://doi.org/10.1007/s00129-017-4123-2", "language": null, "image": "https://media.springernature.com/w200/springer-static/cover/journal/129.jpg", "pagetype": "article", "links": ["#main-content", "https://link.springer.com", "https://link.springer.com/signup-login?previousUrl=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00129-017-4123-2%3Ferror%3Dcookies_not_supported%26code%3Df29823a0-0cdc-4b37-9d55-de44ef29e7ee", "#header-nav", "https://link.springer.com/journals/a/1", "https://www.springernature.com/gp/authors", "#popup-search", "https://order.springer.com/public/cart", "/", "/journal/129", "#article-info", "#auth-T__K_-Eggersmann-Aff1", "#Aff1", "#auth-J_-Gallwas-Aff1", "#Aff1", "#auth-S_-Mahner-Aff1", "#Aff1", "#auth-C_-Dannecker-Aff1", "#Aff1", "/journal/129", "#citeas", "/article/10.1007/s00129-017-4123-2/metrics", "//wayf.springernature.com?redirect_uri=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00129-017-4123-2%3Ferror%3Dcookies_not_supported%26code%3Df29823a0-0cdc-4b37-9d55-de44ef29e7ee", null, "https://www.springernature.com/gp/librarians/licensing/agc/journals", "http://scholar.google.com/scholar_lookup?&title=Human%20Papillomavirus%209%E2%80%91valent%20vaccine%2C%20recombinant%2C%20package%20insert&publication_year=2017", "http://scholar.google.com/scholar_lookup?&title=Human%20Papillomavirus%20bivalent%20%28types%2016%2C18%29%20vaccine%2C%20recombinant%2C%20package%20insert&publication_year=2017", "http://scholar.google.com/scholar_lookup?&title=Human%20Papillomavirus%20Quadrivalent%20%28Types%206%2C11%2C16%2C18%29%20Vaccine%2C%20Recombinant%2C%20Package%20Insert&publication_year=2017", "https://doi.org/10.1056%2FNEJMoa061741", "http://scholar.google.com/scholar_lookup?&title=Quadrivalent%20vaccine%20against%20human%20papillomavirus%20to%20prevent%20high-grade%20cervical%20lesions&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa061741&volume=356&pages=1915-1927&publication_year=2007", "http://scholar.google.com/scholar_lookup?&title=Immunization%20Vaccines%20and%20Biologicals%20-%20HumanPapillomavirus&publication_year=2017", "https://doi.org/10.1016%2FS1470-2045%2810%2970230-8", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20952254", "http://scholar.google.com/scholar_lookup?&title=Human%20papillomavirus%20genotype%20attribution%20in%20invasive%20cervical%20cancer%3A%20A%C2%A0retrospective%20cross-sectional%20worldwide%20study&journal=Lancet%20Oncol.&doi=10.1016%2FS1470-2045%2810%2970230-8&volume=11&pages=1048-1056&publication_year=2010&author=Sanjose%2CS&author=Quint%2CWG&author=Alemany%2CL", "https://doi.org/10.1097%2FAOG.0b013e3181c2ca21", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19935017", "http://scholar.google.com/scholar_lookup?&title=Pregnancy%20and%20infant%20outcomes%20in%20the%20clinical%20trials%20of%20a%C2%A0human%20papillomavirus%20type%206%2F11%2F16%2F18%20vaccine%3A%20A%C2%A0combined%20analysis%20of%20five%20randomized%20controlled%20trials&journal=Obstet%20Gynecol&doi=10.1097%2FAOG.0b013e3181c2ca21&volume=114&pages=1179-1188&publication_year=2009&author=Garland%2CSM&author=Ault%2CKA&author=Gall%2CSA", "https://doi.org/10.1056%2FNEJMoa061760", "/articles/cas-redirect/1:CAS:528:DC%2BD2sXltFSmtLo%3D", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17494926", "http://scholar.google.com/scholar_lookup?&title=Quadrivalent%20vaccine%20against%20human%20papillomavirus%20to%20prevent%20anogenital%20diseases&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa061760&volume=356&pages=1928-1943&publication_year=2007&author=Garland%2CSM&author=Hernandez-Avila%2CM&author=Wheeler%2CCM", "https://doi.org/10.1093%2Fcid%2Fciw354", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27230391", "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967609", "http://scholar.google.com/scholar_lookup?&title=Impact%20and%20effectiveness%20of%20the%20Quadrivalent%20human%20Papillomavirus%20vaccine%3A%20A%20systematic%20review%20of%2010%20years%20of%20real-world%20experience&journal=Clin%20Infect%20Dis&doi=10.1093%2Fcid%2Fciw354&volume=63&pages=519-527&publication_year=2016&author=Garland%2CSM&author=Kjaer%2CSK&author=Munoz%2CN", "https://doi.org/10.1016%2Fj.vaccine.2011.08.106", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21907257", "http://scholar.google.com/scholar_lookup?&title=Monitoring%20the%20safety%20of%20quadrivalent%20human%20papillomavirus%20vaccine%3A%20Findings%20from%20the%20Vaccine%20Safety%20Datalink&journal=Vaccine&doi=10.1016%2Fj.vaccine.2011.08.106&volume=29&pages=8279-8284&publication_year=2011&author=Gee%2CJ&author=Naleway%2CA&author=Shui%2CI", "https://doi.org/10.1080%2F21645515.2016.1168952", "http://scholar.google.com/scholar_lookup?&title=Quadrivalent%20HPV%20vaccine%20safety%20review%20and%20safety%20monitoring%20plans%20for%20nine-valent%20HPV%20vaccine%20in%20the%20United%20States&journal=Hum%20Vaccines%20Immunother&doi=10.1080%2F21645515.2016.1168952&volume=12&pages=1406-1417&publication_year=2016&author=Gee%2CJ&author=Weinbaum%2CC&author=Sukumaran%2CL", "https://doi.org/10.1056%2FNEJMoa0909537", "/articles/cas-redirect/1:CAS:528:DC%2BC3MXhsFGhsLw%3D", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21288094", "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495065", "http://scholar.google.com/scholar_lookup?&title=Efficacy%20of%20quadrivalent%20HPV%20vaccine%20against%20HPV%20Infection%20and%20disease%20in%20males&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa0909537&volume=364&pages=401-411&publication_year=2011&author=Giuliano%2CAR&author=Palefsky%2CJM&author=Goldstone%2CS", "https://doi.org/10.1016%2Fj.vaccine.2015.04.014", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25869893", "http://scholar.google.com/scholar_lookup?&title=Final%20report%20on%20exposure%20during%20pregnancy%20from%20a%C2%A0pregnancy%20registry%20for%20quadrivalent%20human%20papillomavirus%20vaccine&journal=Vaccine&doi=10.1016%2Fj.vaccine.2015.04.014&volume=33&pages=3422-3428&publication_year=2015&author=Goss%2CMA&author=Lievano%2CF&author=Buchanan%2CKM", "https://doi.org/10.1371%2Fjournal.pone.0068329", "/articles/cas-redirect/1:CAS:528:DC%2BC3sXht1Wmt7fN", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23873171", "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714284", "http://scholar.google.com/scholar_lookup?&title=Reduced%20prevalence%20of%20oral%20human%20papillomavirus%20%28HPV%29%204%20years%20after%20bivalent%20HPV%20vaccination%20in%20a%C2%A0randomized%20clinical%20trial%20in%20Costa%20Rica&journal=PLOS%20ONE&doi=10.1371%2Fjournal.pone.0068329&volume=8&publication_year=2013&author=Herrero%2CR&author=Quint%2CW&author=Hildesheim%2CA", "https://doi.org/10.1016%2Fj.vaccine.2014.06.038", "/articles/cas-redirect/1:CAS:528:DC%2BC2cXht1entrbO", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25018097", "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166498", "http://scholar.google.com/scholar_lookup?&title=Efficacy%20of%20the%20HPV-16%2F18%20vaccine%3A%20final%20according%20to%20protocol%20results%20from%20the%20blinded%20phase%20of%20the%20randomized%20Costa%20Rica%20HPV-16%2F18%20vaccine%20trial&journal=Vaccine&doi=10.1016%2Fj.vaccine.2014.06.038&volume=32&pages=5087-5097&publication_year=2014&author=Hildesheim%2CA&author=Wacholder%2CS&author=Catteau%2CG", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24984457", "http://scholar.google.com/scholar_lookup?&title=Deaths%3A%20Preliminary%20data%20for%202011&journal=Natl%20Vital%20Stat%20Rep&volume=61&pages=1-51&publication_year=2012&author=Hoyert%2CDL&author=Xu%2CJ", "http://scholar.google.com/scholar_lookup?&title=Sustained%20Immunogenicity%20of%202%E2%80%91dose%20human%20Papillomavirus%2016%2F18%20AS04-adjuvanted%20vaccine%20schedules%20in%20girls%20aged%209%E2%80%9314%20years%3A%20A%20randomized%20trial&journal=J%20Infect%20Dis&doi=10.1093%2Finfdis%2Fjix154&publication_year=2017&author=Huang%2CLM&author=Puthanakit%2CT&author=Cheng-Hsun%2CC", "https://doi.org/10.1056%2FNEJMoa1405044", "/articles/cas-redirect/1:CAS:528:DC%2BC2MXktF2rsb0%3D", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25693011", "http://scholar.google.com/scholar_lookup?&title=A%209%E2%80%91valent%20HPV%20vaccine%20against%20infection%20and%20intraepithelial%20neoplasia%20in%20women&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1405044&volume=372&pages=711-723&publication_year=2015&author=Joura%2CEA&author=Giuliano%2CAR&author=Iversen%2COE", "https://doi.org/10.1158%2F1940-6207.CAPR-09-0031", "http://scholar.google.com/scholar_lookup?&title=A%20pooled%20analysis%20of%20continued%20prophylactic%20efficacy%20of%20quadrivalent%20human%20papillomavirus%20%28Types%206%2F11%2F16%2F18%29%20vaccine%20against%20high-grade%20cervical%20and%20external%20genital%20lesions&journal=Cancer%20Prev%20Res%20%28Phila%29&doi=10.1158%2F1940-6207.CAPR-09-0031&volume=2&pages=868-878&publication_year=2009&author=Kjaer%2CSK&author=Sigurdsson%2CK&author=Iversen%2COE", "http://scholar.google.com/scholar_lookup?&title=&journal=Epidemiol%20Bull&volume=16&pages=137-138&publication_year=2016", "https://doi.org/10.1016%2FS1470-2045%2811%2970286-8", "/articles/cas-redirect/1:CAS:528:DC%2BC38XkslSlsQ%3D%3D", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22075171", "http://scholar.google.com/scholar_lookup?&title=Overall%20efficacy%20of%20HPV-16%2F18%20AS04-adjuvanted%20vaccine%20against%20grade%203%20or%20greater%20cervical%20intraepithelial%20neoplasia%3A%204%E2%80%91year%20end-of-study%20analysis%20of%20the%20randomised%2C%20double-blind%20PATRICIA%20trial&journal=Lancet%20Oncol.&doi=10.1016%2FS1470-2045%2811%2970286-8&volume=13&pages=89-99&publication_year=2012&author=Lehtinen%2CM&author=Paavonen%2CJ&author=Wheeler%2CCM", "http://scholar.google.com/scholar_lookup?&title=Human%20papillomavirus%20vaccination%3A%20recommendations%20of%20the%20Advisory%20Committee%20on%20Immunization%20Practices%20%28ACIP%29&journal=Morb%20Mortal%20Wkly%20Rep%20Recomm%20Rep&volume=63&pages=1-30&publication_year=2014&author=Markowitz%2CLE&author=Dunne%2CEF&author=Saraiya%2CM", "https://doi.org/10.1542%2Fpeds.2015-2970", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26908690", "http://scholar.google.com/scholar_lookup?&title=Vaccination%20and%2030-day%20mortality%20risk%20in%20children%2C%20adolescents%2C%20and%20young%20adults&journal=Pediatrics&doi=10.1542%2Fpeds.2015-2970&volume=137&publication_year=2016&author=Mccarthy%2CNL&author=Gee%2CJ&author=Sukumaran%2CL", "https://doi.org/10.1016%2Fj.jaci.2015.07.048", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26452420", "http://scholar.google.com/scholar_lookup?&title=Risk%20of%20anaphylaxis%20after%20vaccination%20in%20children%20and%20adults&journal=J.%20Allergy%20Clin.%20Immunol.&doi=10.1016%2Fj.jaci.2015.07.048&volume=137&pages=868-878&publication_year=2016&author=Mcneil%2CMM&author=Weintraub%2CES&author=Duffy%2CJ", "https://doi.org/10.1111%2Fajt.14206", "/articles/cas-redirect/1:STN:280:DC%2BC1czgvFChtw%3D%3D", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28240827", "http://scholar.google.com/scholar_lookup?&title=Use%20of%20a%C2%A02-dose%20schedule%20for%20human%20Papillomavirus%20vaccination-updated%20recommendations%20of%20the%20advisory%20committee%20on%20immunization%20practices&journal=Am.%20J.%20Transplant.&doi=10.1111%2Fajt.14206&volume=17&pages=834-837&publication_year=2017&author=Meites%2CE&author=Kempe%2CA&author=Markowitz%2CLE", "https://doi.org/10.4161%2Fhv.29532", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25424918", "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896780", "http://scholar.google.com/scholar_lookup?&title=Sustained%20efficacy%2C%20immunogenicity%2C%20and%20safety%20of%20the%20HPV-16%2F18%20AS04-adjuvanted%20vaccine%3A%20Final%20analysis%20of%20a%C2%A0long-term%20follow-up%20study%20up%20to%209.4%20years%20post-vaccination&journal=Hum%20Vaccin%20Immunother&doi=10.4161%2Fhv.29532&volume=10&pages=2147-2162&publication_year=2014&author=Naud%2CPS&author=Roteli-Martins%2CCM&author=Carvalho%2CNS", "https://doi.org/10.1016%2FS0140-6736%2809%2961248-4", "/articles/cas-redirect/1:CAS:528:DC%2BD1MXovF2kt78%3D", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19586656", "http://scholar.google.com/scholar_lookup?&title=Efficacy%20of%20human%20papillomavirus%20%28HPV%29-16%2F18%20AS04-adjuvanted%20vaccine%20against%20cervical%20infection%20and%20precancer%20caused%20by%20oncogenic%20HPV%20types%20%28PATRICIA%29%3A%20final%20analysis%20of%20a%C2%A0double-blind%2C%20randomised%20study%20in%20young%20women&journal=Lancet&doi=10.1016%2FS0140-6736%2809%2961248-4&volume=374&pages=301-314&publication_year=2009&author=Paavonen%2CJ&author=Naud%2CP&author=Salmeron%2CJ", "https://doi.org/10.1056%2FNEJMoa1010971", "/articles/cas-redirect/1:CAS:528:DC%2BC3MXhsVSrsrbN", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22029979", "http://scholar.google.com/scholar_lookup?&title=HPV%20vaccine%20against%20anal%20HPV%20infection%20and%20anal%20intraepithelial%20neoplasia&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1010971&volume=365&pages=1576-1585&publication_year=2011&author=Palefsky%2CJM&author=Giuliano%2CAR&author=Goldstone%2CS", "https://doi.org/10.1001%2Fjama.2014.2198", "/articles/cas-redirect/1:CAS:528:DC%2BC2MXnvVWqtrk%3D", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25005658", "http://scholar.google.com/scholar_lookup?&title=Quadrivalent%20human%20papillomavirus%20vaccine%20and%20the%20risk%20of%20venous%20thromboembolism&journal=JAMA&doi=10.1001%2Fjama.2014.2198&volume=312&pages=187-188&publication_year=2014&author=Scheller%2CNM&author=Pasternak%2CB&author=Svanstrom%2CH", "https://doi.org/10.1001%2Fjama.2014.16946", "/articles/cas-redirect/1:CAS:528:DC%2BC2MXit1OnsLo%3D", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25562266", "http://scholar.google.com/scholar_lookup?&title=Quadrivalent%20HPV%20vaccination%20and%20risk%20of%20multiple%20sclerosis%20and%20other%20demyelinating%20diseases%20of%20the%20central%20nervous%20system&journal=JAMA&doi=10.1001%2Fjama.2014.16946&volume=313&pages=54-61&publication_year=2015&author=Scheller%2CNM&author=Svanstrom%2CH&author=Pasternak%2CB", "https://doi.org/10.1016%2FS0140-6736%2814%2960920-X", "/articles/cas-redirect/1:CAS:528:DC%2BC2cXhsVymtr3L", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25189358", "http://scholar.google.com/scholar_lookup?&title=Efficacy%2C%20safety%2C%20and%20immunogenicity%20of%20the%20human%20papillomavirus%2016%2F18%20AS04-adjuvanted%20vaccine%20in%20women%20older%20than%2025%20years%3A%204%E2%80%91year%20interim%20follow-up%20of%20the%20phase%203%2C%20double-blind%2C%20randomised%20controlled%20VIVIANE%20study&journal=Lancet&doi=10.1016%2FS0140-6736%2814%2960920-X&volume=384&pages=2213-2227&publication_year=2014&author=Skinner%2CSR&author=Szarewski%2CA&author=Romanowski%2CB", "https://doi.org/10.1016%2FS1473-3099%2816%2930120-7", "/articles/cas-redirect/1:CAS:528:DC%2BC28XhtV2ns7bK", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27373900", "http://scholar.google.com/scholar_lookup?&title=Efficacy%2C%20safety%2C%20and%20immunogenicity%20of%20the%20human%20papillomavirus%2016%2F18%20AS04-adjuvanted%20vaccine%20in%20women%20older%20than%2025%20years%3A%207%E2%80%91year%20follow-up%20of%20the%20phase%203%2C%20double-blind%2C%20randomised%20controlled%20VIVIANE%20study&journal=Lancet%20Infect%20Dis&doi=10.1016%2FS1473-3099%2816%2930120-7&volume=16&pages=1154-1168&publication_year=2016&author=Wheeler%2CCM&author=Skinner%2CSR&author=Rosario-Raymundo%2CMR", "https://doi.org/10.1002%2Fcam4.869", "/articles/cas-redirect/1:CAS:528:DC%2BC2sXhs1Srsr0%3D", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27998015", "http://scholar.google.com/scholar_lookup?&title=Efficacy%2C%20immunogenicity%2C%20and%20safety%20of%20the%20HPV-16%2F18%20AS04-adjuvanted%20vaccine%20in%20Chinese%20women%20aged%2018%E2%80%9325%20years%3A%20Event-triggered%20analysis%20of%20a%C2%A0randomized%20controlled%20trial&journal=Cancer%20Med&doi=10.1002%2Fcam4.869&volume=6&pages=12-25&publication_year=2017&author=Zhu%2CFC&author=Hu%2CSY&author=Hong%2CY", "https://citation-needed.springer.com/v2/references/10.1007/s00129-017-4123-2?format=refman&flavour=references", "/search?dc.creator=T.%20K.%20Eggersmann", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=T.%20K.%20Eggersmann", "http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22T.%20K.%20Eggersmann%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en", "/search?dc.creator=J.%20Gallwas", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=J.%20Gallwas", "http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22J.%20Gallwas%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en", "/search?dc.creator=S.%20Mahner", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=S.%20Mahner", "http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22S.%20Mahner%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en", "/search?dc.creator=C.%20Dannecker", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=C.%20Dannecker", "http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22C.%20Dannecker%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en", "mailto:Tanja.Eggersmann@med.uni-muenchen.de", "https://s100.copyright.com/AppDispatchServlet?title=Impfung%20gegen%20humane%20Papillomviren.%20Wirksamkeit%20und%20Nebenwirkungen&author=T.%20K.%20Eggersmann%20et%20al&contentID=10.1007%2Fs00129-017-4123-2&copyright=Springer%20Medizin%20Verlag%20GmbH&publication=0017-5994&publicationDate=2017-08-23&publisherName=SpringerNature&orderBeanReset=true", "https://crossmark.crossref.org/dialog/?doi=10.1007/s00129-017-4123-2", "https://citation-needed.springer.com/v2/references/10.1007/s00129-017-4123-2?format=refman&flavour=citation", "/search?query=Zervikale%20intraepitheliale%20Neoplasie%20&facet-discipline=%20Medicine%20%26%20Public%20Health%20", "/search?query=Zervixkarzinom&facet-discipline=%20Medicine%20%26%20Public%20Health%20", "/search?query=Analkanal&facet-discipline=%20Medicine%20%26%20Public%20Health%20", "/search?query=Unerw%C3%BCnschte%20Effekte&facet-discipline=%20Medicine%20%26%20Public%20Health%20", "/search?query=Immunisierung&facet-discipline=%20Medicine%20%26%20Public%20Health%20", "/search?query=Cervical%20intraepithelial%20neoplasia&facet-discipline=%20Medicine%20%26%20Public%20Health%20", "/search?query=Cervical%20cancer&facet-discipline=%20Medicine%20%26%20Public%20Health%20", "/search?query=Anal%20canal&facet-discipline=%20Medicine%20%26%20Public%20Health%20", "/search?query=Adverse%20effects&facet-discipline=%20Medicine%20%26%20Public%20Health%20", "/search?query=Immunization&facet-discipline=%20Medicine%20%26%20Public%20Health%20", "//wayf.springernature.com?redirect_uri=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00129-017-4123-2%3Ferror%3Dcookies_not_supported%26code%3Df29823a0-0cdc-4b37-9d55-de44ef29e7ee", null, "https://www.springernature.com/gp/librarians/licensing/agc/journals", "https://link.springer.com/journals/a/1", "https://www.springernature.com/gp/authors", "https://link.springer.com/journals/a/1", "https://link.springer.com/books/a/1", "https://www.springernature.com/gp/authors", "https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research", "https://www.springernature.com/gp/products", "https://www.springernature.com/gp/librarians", "https://www.springernature.com/gp/societies", "https://www.springernature.com/gp/partners", "https://www.springer.com/", "https://www.nature.com/", "https://www.biomedcentral.com/", "https://www.palgrave.com/", "https://www.apress.com/", "https://www.springernature.com/gp/legal/ccpa", "https://www.springernature.com/gp/info/accessibility", "https://link.springer.com/termsandconditions", "https://link.springer.com/privacystatement", "https://support.springernature.com/en/support/home", "https://www.springernature.com/"]}